Sanofi Aktie

51,50 EUR +0,50 EUR +0,98 %

16:12:11

FSE

54,71 USD +0,79 USD +1,46 %

20:38:12

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

KGV19,43

WKN662283

ISINUS80105N1054

SymbolSNY

Sanofi Aktien News

Sortieren:Datum Meistgelesen

19.04.23GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - March 2023

11.04.23GlobeNewswirePress Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements

10.04.23GlobeNewswirePress Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.

04.04.23PR NewswireSanofi Breaks Ground on State-of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines

04.04.23GlobeNewswirePress Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia

30.03.23GlobeNewswirePress Release: Availability of the Q1 2023 Memorandum for modelling purposes

23.03.23GlobeNewswirePress Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial

21.03.23GlobeNewswirePress Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis

18.03.23GlobeNewswirePress Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

16.03.23GlobeNewswirePress Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

14.03.23GlobeNewswireInformation concerning the total number of voting rights and shares – February 2023

13.03.23GlobeNewswirePress Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

07.03.23GlobeNewswirePress Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

02.03.23GlobeNewswirePress Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A

24.02.23GlobeNewswireALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)

24.02.23GlobeNewswirePress release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease

23.02.23GlobeNewswirePress Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

15.02.23GlobeNewswireSanofi: Information concerning the total number of voting rights and shares – January 2023

13.02.23GlobeNewswirePress Release: Sanofi announces change in R&D leadership

03.02.23MyDividendsSanofi erhöht die Dividende das 29. Jahr in Folge

18.01.23PR NewswireSanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare

21.12.22PR NewswirePositive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine

16.12.22PR NewswireDupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis

15.12.22PR NewswireDupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis

17.11.22GlobeNewswirePress Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease

11.11.22GlobeNewswirePress Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis

11.11.22PR NewswireDupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis

10.11.22GlobeNewswirePress Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission

04.11.22GlobeNewswirePress Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants

28.10.22GlobeNewswirePress Release: Continued strong growth in Q3 with key regulatory milestones achieved

11.10.22GlobeNewswirePress Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old

11.10.22PR NewswireDupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old

06.10.22PR NewswireSanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes

29.09.22GlobeNewswirePress Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

28.09.22PR NewswireDupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis

28.09.22GlobeNewswirePress Release: Availability of the Q3 2022 Memorandum for modelling purposes

16.09.22GlobeNewswirePress Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants

08.09.22GlobeNewswirePress Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis

08.09.22PR NewswireDupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis

05.09.22PR NewswireLate-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.